Acceleron Careers


At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for rare blood disorders and pulmonary diseases.

  • Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling. The U.S. Food and Drug Administration has approved REBLOZYL® (luspatercept-aamt) for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell (RBC) transfusions and for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
  • In our pulmonary program, we are developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial and actively enrolling patients in the Phase 2 SPECTRA trial.

The clinical trials listed below are Acceleron or partner-sponsored trials, some of which are actively recruiting patients. Each trial in the list contains a link to, where you will find a full description and contact information.

Drug Study Phase Disease
Luspatercept COMMANDS Phase III* Low or Intermediate Risk MDS
Luspatercept BEYOND Phase II* Beta-Thalassemia
Luspatercept Phase II* Myelofibrosis
Luspatercept Phase II Extension MDS
Luspatercept Phase II Extension Beta-Thalassemia
Luspatercept Phase II Anemia in Lower-Risk MDS
Luspatercept Phase II Beta-Thalassemia
Sotatercept PULSAR Phase II Pulmonary Arterial Hypertension
Sotatercept SPECTRA Phase II Pulmonary Arterial Hypertension
Acceleron trials listed as recruiting or active on

* Bristol-Myers Squibb-sponsored